Creapharm, BioConvergence Bridge Services

BioConvergence and Creapharm have partnered in an effort to provide customers with lower costs, reduced risks, and increased control of projects. The partnership — called the “Transatlantic Bridge” — aims to combine pharmaceutical services and provide integrated, customized services with innovative, transparent, and effective solutions, without adding the resources and costs associated with managing multiple partners.

The “Transatlantic Bridge” provides access to North America from Europe and Europe from North America through a single point of contact that manages all aspects of the project including contract management, project management, product development, production, testing, and clinical supply services. The companies manage critical path initiatives using their collective geographic presence and regulatory knowledge. Clients will acquire project information using E-Transparency System, a secure portal providing real-time access to development, production, supply chain and quality data.

“I’m pleased to announce that through our collaboration with Creapharm, we will deliver new sourcing, contracting, and management options designed to optimize early clinical development, production, testing, and supply chain design and execution. By doing so, our clients will realize results they value,” Alisa Wright, chief executive officer, BioConvergence LLC.

“Creapharm is one of the leaders in Europe for pharmaceutical development and clinical supplies, but until now has had no operations in North America, which is and will remain the number one territory for clinical studies. Through our collaboration with BioConvergence I am pleased to announce that we can now provide to our European clients a “Transatlantic Bridge,” a seamless extended supply service of the highest quality for clinical studies in North America,” said Michel Pautrat, chief executive officer, Creapharm Europe.